From NICNAS To AICIS: Australia’s Chemical Regulatory Reform
In Australia, the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) is the actual entity responsible for controlling cosmetics. After July 1st, 2020, NICNAS will be replaced by a new scheme called Australian Industrial Chemicals Introduction Scheme (AICIS).


In Australia, chemicals are regulated depending on their use. If a chemical is not for a therapeutic, agricultural, veterinary or food use, it is considered an industrial chemical. Nearly all cosmetic ingredients are regulated as industrial chemicals under the Industrial Chemicals (Notification and Assessment) Act 1989 (ICNA Act), which is at date administered by NICNAS.

The Industrial Chemicals Act 2019 (IC Act 2019) establishes a new regulatory scheme, called the Australian Industrial Chemicals Introduction Scheme (AICIS), for the importation and manufacture of industrial chemicals in Australia. Chemicals with an industrial use will be now regulated by AICIS.

The framework for managing the transition from the old scheme to the new is set out by the new legislation (the Industrials Chemicals (Consequential Amendments and Transitional Provisions) Act 2019), in addition to IC Act 2019. Three new Industrial Chemicals Charges Acts, authorizing the imposition of charges on importers and manufacturers of industrial chemicals to recover the costs of administering the new scheme, will also take place: Industrial Chemicals Charges (Customs) Act 2019; Industrial Chemicals Charges (Excise) Act 2019; Industrial Chemicals Charges (General) Act 2019.

The Australian Inventory of Chemical Substances (AICS) lists more than 40 000 industrial chemicals that can be manufactured or imported into Australia. AICS contains chemical identity information and regulatory obligations regarding that chemical.

At 30th June 2020, NICNAS website will be archived by the National Library of Australia, but it will remain accessible. A new website web address (AICIS) will be available from July 1st, 2020.


The new scheme (IC Act 2019) implements the ban on the use of new animal test data for ingredients used solely in cosmetics.

After July 1st, 2020, the new inventory will be called Australian Inventory of Industrial Chemicals (AIIC) instead of AICS, and it will be generally referred to as ‘the Inventory’. Although the NICNAS Inventory listed many chemicals that had never had an industrial use, the new Inventory will not list these chemicals.

Regarding chemicals under NICNAS exemptions, companies may introduce these chemicals until 31st August 2022. After this date, companies need to categorize their introduction (explained ahead) to make sure they are compliant with AICIS. The following exemptions are included in this arrangement: R&D (less than 100 kg), no unreasonable risk in cosmetics (less than 100 kg), no unreasonable risk in non-cosmetics (less than 100 kg), and non-hazardous in cosmetics (less than 1%)

Companies which are already registered with NICNAS at 30th June 2020 do not need to do any new registration, as their registration will automatically transfer to AICIS on 1st July 2020, keeping the same registration ID. After 31st August 2020, if companies continue introducing industrial chemicals, they need to renew their registration by 1st September 2020 (online in AICIS Business Services).

When registering a business, before import or manufacture (introduce) an industrial chemical, each chemical must be authorized under 1 of 5 main categories (called introduction categories). These categories are:

  • Listed
    • Already on the Inventory and available for industrial use in Australia.
  • Exempted
    • Considered by AICIS as very low risk to human health and to the environment.
  • Reported
    • Considered by AICIS as low risk to human health and to the environment
  • Assessed
    • Considered by AICIS as medium to high risk to human health and the environment.
  • Commercial evaluation
    • Application for a time-limited Commercial Evaluation Authorisation for the purpose of testing a chemical’s commercial viability in Australia.

Regardless of the introduction category, every introducer must submit an annual declaration at the end of every registration year.

From July 1st 2020, Australian Industrial Chemicals Introduction Scheme (AICIS) will replace the current National Industrial Chemicals Notification and Assessment Scheme (NICNAS), established by a new regulatory scheme (the Industrial Chemicals Act 2019 (IC Act 2019)).

All in all, importers and manufacturers introducing industrial chemicals into Australia for commercial purposes must:

  • Register their business and pay a fee (if not already registered with NICNAS).
  • Categorize each chemical importation or manufacture (introduction) into 1 of 5 categories.

Importers and manufacturers have also the responsibility to submit declarations and reports, to keep records and give information to AICIS when asked.


  1. Australian Government, Department of Health – National Industrial Chemicals Notification and Assessment Scheme (NICNAS) – Cosmetics and Therapeutic Goods –
  2. Australian Industrial Chemicals Introduction Scheme – Fact Sheet –
  3. Australian Government – Industrial Chemicals (Notification and Assessment) Act 1989 (ICNA Act)
  4. Australian Government – Industrial Chemicals Act 2019
  5. Australian Government – Industrial Chemicals (Consequential Amendments and Transitional Provisions) Act 2019
  6. Australian Industrial Chemicals Introduction Scheme (AICIS) – Industrial Chemicals Categorisation Guidelines – Final Draft, 2019


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »